-
Vanderbilt-Discovered Compound Advances to Phase 1 Clinical Trial as a Promising New Treatment for Schizophrenia
Neumora Therapeutics, Inc. has announced the launch of a Phase 1 clinical study evaluating NMRA-861 in healthy adult participants and adults with stable schizophrenia. -
From Lab to Market: Turning Medical Breakthroughs into Business Ventures
Vanderbilt's Center for Technology Transfer and Commercialization (CTTC) is proud to be featured in an article from the School of Medicine, Basic Sciences highlighting our dedication to fostering innovation and transforming groundbreaking ideas into real-world solutions.